Immunological recovery and tumour-specific immunotherapeutic approaches to post-autologous haematopoietic stem cell transplantation

Bailliere's Best Practice in Clinical Haematology

Volumn 12, Issue 1-2, 1999, Pages 293-306

  Guillaume, Thierry ^a,c   Rubinstein, Daniel B ^b   Symann, Michel ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Adoptive T cell therapy; Autologous haematopoietic stem cell transplantation; Dendritic cells; Immune reconstitution; Immunotherapy; Tumour vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; TUMOR ANTIGEN; TUMOR VACCINE;

AUTOTRANSPLANTATION; CELLULAR IMMUNITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOTHERAPY; LYMPHOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOLID TUMOR; T LYMPHOCYTE;

EID: 0032713312     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0024     Document Type: Article

References (92)

1. Small TN, Keever CA, Weiner-Fedus S et al. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 1990; 76: 1647-1656.
2. Storek J, Ferrara S, Ku N et al. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone marrow Transplantation 1993; 12: 387-398.
3. Bengtsson M, Smedmyr B, Festin R et al. B lymphocyte regeneration in marrow and blood after autologous bone marrow transplantation: increased numbers of B cells carrying activation and progression markers. Leukemia Research 1989; 13: 791-797.
4. Fumoux F, Guigou V, Blaise D et al. Reconstitution of human immunoglobulin VH repertoire after bone marrow transplantation mimics B-cell ontogeny. Blood 1993; 81: 3153-3157.
5. Storek J, King L, Ferrara S et al. Abundance of a restricted fetal B cell repertoire in marrow transplant recipients. Bone Marrow Transplantation 1994; 14: 783-790.
6. Saxon A, Mitsuyasu R, Stevens R et al. Designed transfer of specific immune responses with bone marrow transplantation. Journal of Clinical Investigation 1986; 78: 959-967.
7. Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; i: 339-343.
8. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplantation 1993; 11: 1-5.
9. Witherspoon RP, Lum LG, Storb R & Thomas ED. In vitro regulation of immunoglobulin synthesis after human marrow transplantation. II. Deficient T and non T-lymphocyte function within 3-4 months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy. Blood 1982; 59: 844-850.
10. Kiesel S, Pezzutto A, Moldenhauer G et al. B-cell proliferative and differentiative responses after autologous peripheral blood stem cell or bone marrow transplantation. Blood 1988; 72: 672-678.
11. Armitage RJ, Goldstone AH, Richards JDM & Cawley JC. Lymphocyte function after autologous bone marrow transplantation (BMT): a comparison with patients treated with allogeneic BMT and with chemotherapy only. British Journal of Haematology 1986; 63: 637-647.
12. Hénon PR, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplantation 1992; 9: 285-291.
13. Koehne G, Zeller W, Stockschlaeder M & Zander AR. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1997; 19: 149-156.
14. Ho AD, Maruyama M, Maghazachi A et al. Soluble CD4, soluble CD8, Soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood 1994; 84: 3550-3557.
15. Kiesel S, Pezzutto A, Körbling M et al. Autologous peripheral blood stem cell transplantation: Analysis of autografted cells and lymphocyte recovery. Transplantation Proceedings 1989; 21: 3084-3088.
16. Talmadge JE, Reed EC, Kessinger A et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplantation 1996; 17: 101-109.
17. Talmadge JE, Reed E, Ino K et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplantation 1997; 19: 161-172.
18. Ashihara E, Shimazaki C, Yamagata N et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplantation 1994; 13: 377-381.
19. Mackall CL, Hakim FT & Gress RE. T-cell regeneration: all repertoires are not created equal. Immunology Today 1997; 18: 245-251.
20. - T cells, a memory subset with preferential interleukin-4 production, after bone marrow transplantation. Transplantation 1997; 64: 1453-1459.
21. Weaver CH, Longin K, Buckner CD & Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplantation 1994; 13: 411-415.
22. Ottinger HD, Beelen DW, Scheulen B et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cell instead of bone marrow. Blood 1996; 88: 2275-2779.
23. + T-lymphocyte regeneration after intensive chemotherapy. New England Journal of Medicine 1995; 332: 143-149.
24. Storek J, Witherspoon RP & Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplantation 1995; 16: 413-425.
25. Weinberg K, Annett GM, Kashyap A et al. The effect of thymic function on immunocompetence following bone marrow transplantation. Biology of Blood and Marrow Transplantation 1995; 1: 18-23.
26. Steinmann GG, Klaus B & Müller-Hermelink H-K. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scandinavian Journal of Immunology 1985; 22: 563-575.
27. Mackall CL, Granger L, Sheard MA et al. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993; 82: 2585-2594.
28. Mackall CL, Bare CV, Granger LA et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. Journal of Immunology 1996; 156: 4609-4616.
29. +T-cell receptor γ/δ T-cells early after bone marrow transplantation. Blood 1991; 78: 1875-1881.
30. Villers D, Milpied N, Gaschet J et al. Alteration of the T cell repertoire after bone marrow transplantation. Bone Marrow Transplantation 1994; 13: 19-26.
31. + T-cells with restricted T-cell receptor b chain variability after bone marrow transplantation. Blood 1994; 83: 587-595.
32. Gaschet J, Denis C, Milpied N et al. Alterations of T cell repertoire after bone marrow transplantation: characterization of over-represented subsets. Bone Marrow Transplantation 1995; 16: 427-435.
33. + hematopoietic progenitors. Blood 1998; 91: 2588-2600.
34. Reusser P, Attenhofer R, Hebart H et al. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997; 89: 3873-3879.
35. Nolte A, Buhmann R, Straka C et al. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1998; 21: 909-916.
36. Reittie JE, Gottlieb D, Heslop HE et al. Endogenously generated killer cells circulate after autologous and allogeneic marrow transplantation but not chemotherapy. Blood 1989; 73: 1352-1358.
37. Higuchi CM, Thompson JA, Cox T et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Research 1989; 49: 5509-5513.
38. Neubauer MA, Benyunes MC, Thomson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1994; 13: 311-316.
39. Fegan C, Thomas H, Bailey-Wood R et al. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995; 16: 277-271.
40. Lum LG, Joshi ID, Galoforo SC et al. Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients. Bone Marrow Transplantation 1993; 12: 565-571.
41. + cells even in the presence of exogeneous IL-2. Blood 1989; 74: 2270-2277.
42. Cayeux S, Meuer S, Pezzutto A et al. Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogenous IL-2. Blood 1989; 74: 2278-2284.
43. Guillaume Th, Sekhavat M, Rubinstein DB et al. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin, and lack of evidence for a role for IL-10 in delayed immune reconstitution. Cancer Research 1994; 54: 3800-3807.
44. Bosly AE, Staquet PJ, Doyen CM et al. Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. Experimental Hematology 1987; 15: 1048-1054.
45. Bosly A, Guillaume T, Brice P et al. Effects of escalating doses of recombinant human interleukin-2 (r-IL-2) in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Experimental Hematology 1992; 20: 962-968.
46. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplantation 1993; 12: 469-475.
47. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper type I and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
48. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. Journal of Experimental Medicine 1993; 178: 1223-1230.
49. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. Journal of Immunology 1994; 153: 1697-1706.
50. Guillaume Th, Kubin M, Sekhavat M et al. Peripheral blood mononuclear cells derived from patients undergoing autologous hematopoietic stem cell transplantation produce and respond to IL-12. Bone Marrow Transplantation 1996; 18: 733-739.
51. Lindgren CG, Thompson JA, Robinson N et al. Interleukin-12 induces cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants. Bone Marrow Transplantation 1997; 19: 867-872.
52. Dorshkind K, Pollack SB, Bosma MJ & Phillips RA. Natural killer cells are present in mice with severe combined immunodeficiency (SCID). Journal of Immunology 1985; 134: 3798-3801.
53. Reichardt VL, Okada CY, Stockerl-Goldstein KE et al. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biology of Blood and Marrow Transplantation 1997; 3: 157-163.
54. Gambacorti-Passerini C, Grignani F, Arienti F et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375.
55. Bocchia M, Korontsvit T, Xu Q et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
56. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996; 88: 3522-3527.
57. Buzyn A, Ostankovitch M, Zerbib A et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. European Journal of Immunology 1997; 27: 2066-2072.
58. van den Eynde BJ & van der Bruggen P. T cell defined tumor antigens. Current Opinion in Immunology 1997; 9: 684-693.
59. Barnd DL, Lan MS, Metzgar RS & Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proceedings of the National Academy of Sciences of the USA 1989; 86: 7159-7163.
60. Ioannides CG, Fisk B, Jerome KR et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptide. Journal of Immunology 1993; 151: 3963-3703.
61. Disis ML, Smith JW, Murphy AE et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Research 1994; 54: 1071-1076.
62. Houbiers JGA, Nijman HW, van der Burg SH et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type. European Journal of Immunology 1993; 23: 2072-2077.
63. Pardoll DM. Cancer vaccines. Nature Medicine 1998; 4: 525-531.
64. Kwak LW, Cambell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine 1992; 327: 1209-1215.
65. Kwak LW. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Annals of Oncology 1998; 9 (supplement 1): S41-S46.
66. Kwak LW, Campbell MJ, Zelenetz AD et al. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. 1990; Blood 76: 2411-2417.
67. Kwak LW, Sternas LA, Jagannath S et al. T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood 1997; 90 (supplement 1): 579a.
68. Kwak LW, Pennington R & Longo DL. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996; 87: 3053-3060.
69. Riddell SR & Greenberg PD. Cellular adoptive immunotherapy after bone marrow transplantation. Cancer Treatment Research 1995; 76: 337-369.
70. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 1992; 257: 238-241.
71. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine 1995; 333: 1038-1044.
72. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine 1996; 2: 551-555.
73. Banchereau J & Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
74. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro, with tumor antigen induce tumor resistance in vivo. European Journal of Immunology 1994; 24: 605-610.
75. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Medicine 1995; 1: 1297-1302.
76. Paglia P, Chiodoni C, Rodolfo M & Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. Journal of Experimental Medicine 1996; 183: 317-322.
77. Porgador A, Snyder D & Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. Journal of Immunology 156: 2918-2926.
78. Hsu FJ, Benike C, Fagnoni F et al. Vaccinations of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine 1996; 2: 52-58.
79. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 1998; 4: 328-332.
80. Fisk B, Blevins TL, Taylor Wharton J & Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. Journal of Experimental Medicine 1995; 181: 2109-2117.
81. Storkus WJ, Zeh HJ, Salter RD & Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. Journal of Immunotherapy 1993; 14: 94-103.
82. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines. Journal of Experimental Medicine 1996; 183: 87-97.
83. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Research 1995; 55: 1099-1104.
84. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. Journal of Immunology 1995; 154: 5851-5861.
85. + blood progenitors for anticancer therapy. Experimental Hematology 1995; 23: 1463-1471.
86. + hematopoietic progenitor cells in cancer patients. European Journal of Immunology 1996; 26: 595-600.
87. Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. Journal of Immunological Methods 1996; 196: 137-151.
88. Henderson RA, Nimgaonkar MT, Watkins SC et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-I). Cancer Research 1996; 56: 3763-3770.
89. Reeves ME, Royal RE, Lam JS et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Research 1996; 56: 5672-5677.
90. Aicher A, Westermann J, Cayeux S et al. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. Experimental Hematology 1997; 25: 39-44.
91. Ribas A, Butter-field LH & McBride WH. Genetic immunization for the melanoma antigen MART-I/ Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Research 1997; 57: 2865-2869.
92. Song W, Kong H-L, Carpenter H et al. Dendritic cells modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. Journal of Experimental Medicine 1997; 186: 1247-1256.